Back to search results

Cosmetic Evaluation of Ariessence™ Pure PDGF+ After Laser Treatment

This study is evaluating a product called ariessence pure PDGF+™ (which contains Hyaluronic Acid and platelet-derived growth factor, or PDGF) for use after ablative laser procedures. Researchers want to see if ariessence helps with recovery and improves skin appearance compared to standard aftercare (Aquaphor). You might be able to join if you are between 40 and 70 years old, have specific skin types (Glogau III-IV and Fitzpatrick II-IV), are suitable for ablative laser, and are a non-smoker. The study will measure how well you tolerate the procedure, your satisfaction, and changes in your skin's appearance using photos and ratings. The current recruitment status is unclear.

Study design
This interventional study plans to enroll 21 participants to compare ariessence pure PDGF+™ to standard care after ablative laser treatment.
What's involved
You would need to comply with a post-procedure regimen, document your outcomes, and have photos taken from the start of the study through Day 84.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 84 days after the start of the study, with measurements taken at various points during this time.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07718347

Post-market Cosmetic Evaluation of Ariessence™ Pure PDGF+ Following Ablative Laser

Recruiting
NAAges 40–70InterventionalTreatment
Lynch Regenerative Medicine
~21 participants
Updated 2026-07-21 on ClinicalTrials.gov
What's tested:ariessence pure PDGF+™ is a sterile aqueous formulation containing Hyaluronic Acid and pure platelet-derived growth factor (PDGF).

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Clinical Measures
Measured over Baseline (Day 0) through Day 84 (End of Study).
+5 more outcomes measured

Conditions

Immediate Post-Treatment Care
Aging Mid-Face
Aging

Explore related trials

Aging Mid-FaceHanging skinPost-Laser Treatment

Where it's being run

2 sites across 2 states
California1
Tennessee1

Who to contact

Josh Arnold
[email protected]
302-604-4532
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

:Adults 40-65 70 years
Glogau III-IV
Fitzpatrick II-IV.
Suitable for ablative laser
non-smoker ≥ 3 years
Willing to comply with post-procedure regimen
patient reported outcome documentation, and photo documentation.

Exclusion

Fitzpatrick I or \> IV,
recent facial procedures (\< 6 months)
active skin disease
pregnancy/lactation
implanted devices
history of keloids.

What this trial measures

  • Clinical MeasuresBaseline (Day 0) through Day 84 (End of Study).

    Glogau Scale

  • Patient-Reported OutcomesBaseline through day 84

    FACE-Q, SKIN-Q, FACE-Q Psychological Function, treatment Discomfort/Pain Evaluation Subject Satisfaction Scale

  • PhotographyBaseline through Day 84

    VISIA-CR (standardized frontal ±45°), FitSkin (regional close-ups), and point-and-shoot baseline and follow-ups

  • Investigator Objective Tolerability AssessmentBaseline through Day 84

    Tolerability of product

  • Erythema grading (0-4 scale)Baseline through Day 84 (End of Study)

    Degree of erthema

  • Clinician's Global Aesthetic Improvement Scale (CGAIS).Baseline through Day 84 (End of STudy)

    Measure of Aestetic Imporvement